Treatment of ALK− ALCL tumor bearing mice carrying JAK1 and STAT3 mutations with ruxolitinib, a JAK1/JAK2 inhibitor, led to inhibition of tumor formation, which demonstrates the therapeutic potential of targeting the JAK1/STAT3 pathway [22]. Here, ALK is linked to anaplastic large cell lymphoma.